Serum microRNA-34a as a circulating biomarker for age-related macular degeneration and short-term anti-VEGF response in neovascular AMD
Meng Kong, Rong Jin, Tongjie Cheng, Li Sun, Nianting Tong · 2026
Read Serum microRNA-34a as a circulating biomarker for age-related macular degeneration and short-term anti-VEGF response in neovascular AMD by Meng Kong, Rong Jin, Tongjie Cheng, Li Sun, Nianting Tong (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13449471.txt.
Description
Meng Kong and colleagues tested a blood marker for macular degeneration in a 2026 study from Qingdao. Age-related macular degeneration damages central vision, and its wet form is treated with anti-VEGF injections into the eye. Doctors lack a simple blood test to flag the disease or predict who will respond well to those injections.
The team measured serum microRNA-34a in 160 patients and 122 matched healthy controls, staging disease by standard criteria. Patients with wet disease received three monthly injections and were classed as good or poor responders by eye scans and vision tests. MicroRNA-34a ran higher in patients than in controls, and baseline levels were tested against short-term response. The marker may one day help triage and counsel patients starting therapy.
Catalog record
| CREATOR | Meng Kong, Rong Jin, Tongjie Cheng, Li Sun, Nianting Tong |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |